These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 20525919)

  • 21. Feasibility of clofarabine cytoreduction before allogeneic transplant conditioning for refractory AML.
    Locke FL; Artz A; Rich E; Zhang Y; van Besien K; Stock W
    Bone Marrow Transplant; 2010 Dec; 45(12):1692-8. PubMed ID: 20208570
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dosing-time contributes to chronotoxicity of clofarabine in mice via means other than pharmacokinetics.
    Luan JJ; Zhang YS; Liu XY; Wang YQ; Zuo J; Song JG; Zhang W; Wang WS
    Kaohsiung J Med Sci; 2016 May; 32(5):227-34. PubMed ID: 27316580
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of pharmacokinetics on the toxicity and efficacy of clofarabine in patients with relapsed or refractory acute myeloid leukemia.
    Büttner B; Knoth H; Kramer M; Oertel R; Seeling A; Sockel K; von Bonin M; Stölzel F; Alakel N; Platzbecker U; Röllig C; Ehninger G; Bornhäuser M; Schetelig J; Middeke JM
    Leuk Lymphoma; 2017 Dec; 58(12):2865-2874. PubMed ID: 28509593
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Phase I Study of Clofarabine With Multiagent Chemotherapy in Childhood High Risk Relapse of Acute Lymphoblastic Leukemia (VANDEVOL Study of the French SFCE Acute Leukemia Committee).
    Nelken B; Cave H; Leverger G; Galambrun C; Plat G; Schmitt C; Thomas C; Vérité C; Brethon B; Gandemer V; Bertrand Y; Baruchel A; Rohrlich P
    Pediatr Blood Cancer; 2016 Feb; 63(2):270-5. PubMed ID: 26376115
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase I trial of high-dose clofarabine, etoposide, and cyclophosphamide and autologous peripheral blood stem cell transplantation in patients with primary refractory and relapsed and refractory non-Hodgkin lymphoma.
    Srivastava S; Jones D; Wood LL; Schwartz JE; Nelson RP; Abonour R; Secrest A; Cox E; Baute J; Sullivan C; Kane K; Robertson MJ; Farag SS
    Biol Blood Marrow Transplant; 2011 Jul; 17(7):987-94. PubMed ID: 20965266
    [TBL] [Abstract][Full Text] [Related]  

  • 26. AAML0523: a report from the Children's Oncology Group on the efficacy of clofarabine in combination with cytarabine in pediatric patients with recurrent acute myeloid leukemia.
    Cooper TM; Alonzo TA; Gerbing RB; Perentesis JP; Whitlock JA; Taub JW; Horton TM; Gamis AS; Meshinchi S; Loken MR; Razzouk BI
    Cancer; 2014 Aug; 120(16):2482-9. PubMed ID: 24771494
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia.
    Inaba H; Rubnitz JE; Coustan-Smith E; Li L; Furmanski BD; Mascara GP; Heym KM; Christensen R; Onciu M; Shurtleff SA; Pounds SB; Pui CH; Ribeiro RC; Campana D; Baker SD
    J Clin Oncol; 2011 Aug; 29(24):3293-300. PubMed ID: 21768474
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A novel clofarabine bridge strategy facilitates allogeneic transplantation in patients with relapsed/refractory leukemia and high-risk myelodysplastic syndromes.
    Locke F; Agarwal R; Kunnavakkam R; van Besien K; Larson RA; Odenike O; Godley LA; Liu H; Le Beau MM; Gurbuxani S; Thirman MJ; Sipkins D; White C; Artz A; Stock W
    Bone Marrow Transplant; 2013 Nov; 48(11):1437-43. PubMed ID: 23771005
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Remission re-induction chemotherapy with clofarabine, topotecan, thiotepa, and vinorelbine for patients with relapsed or refractory leukemia.
    Steinherz PG; Shukla N; Kobos R; Steinherz L
    Pediatr Blood Cancer; 2010 May; 54(5):687-93. PubMed ID: 20205253
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HLA haploidentical hematopoietic cell transplantation using clofarabine and busulfan for refractory pediatric hematological malignancy.
    Takagi M; Ishiwata Y; Aoki Y; Miyamoto S; Hoshino A; Matsumoto K; Nishimura A; Tanaka M; Yanagimachi M; Mitsuiki N; Imai K; Kanegane H; Kajiwara M; Takikawa K; Mae T; Tomita O; Fujimura J; Yasuhara M; Tomizawa D; Mizutani S; Morio T
    Int J Hematol; 2017 May; 105(5):686-691. PubMed ID: 28185203
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia.
    Jeha S; Gaynon PS; Razzouk BI; Franklin J; Kadota R; Shen V; Luchtman-Jones L; Rytting M; Bomgaars LR; Rheingold S; Ritchey K; Albano E; Arceci RJ; Goldman S; Griffin T; Altman A; Gordon B; Steinherz L; Weitman S; Steinherz P
    J Clin Oncol; 2006 Apr; 24(12):1917-23. PubMed ID: 16622268
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia.
    Jeha S; Gandhi V; Chan KW; McDonald L; Ramirez I; Madden R; Rytting M; Brandt M; Keating M; Plunkett W; Kantarjian H
    Blood; 2004 Feb; 103(3):784-9. PubMed ID: 14551141
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome.
    Faderl S; Garcia-Manero G; Estrov Z; Ravandi F; Borthakur G; Cortes JE; O'Brien S; Gandhi V; Plunkett W; Byrd A; Kwari M; Kantarjian HM
    J Clin Oncol; 2010 Jun; 28(16):2755-60. PubMed ID: 20421540
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clofarabine, cyclophosphamide and etoposide for the treatment of relapsed or resistant acute leukemia in pediatric patients.
    Miano M; Pistorio A; Putti MC; Dufour C; Messina C; Barisone E; Ziino O; Parasole R; Luciani M; Lo Nigro L; De Rossi G; Varotto S; Bertorello N; Petruzziello F; Calvillo M; Micalizzi C
    Leuk Lymphoma; 2012 Sep; 53(9):1693-8. PubMed ID: 22303898
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I/II trial of clofarabine and cytarabine in children with relapsed/refractory acute lymphoblastic leukemia (AAML0523): a report from the Children's Oncology Group.
    Cooper TM; Razzouk BI; Gerbing R; Alonzo TA; Adlard K; Raetz E; Gamis AS; Perentesis J; Whitlock JA
    Pediatr Blood Cancer; 2013 Jul; 60(7):1141-7. PubMed ID: 23335239
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clofarabine salvage therapy in refractory multifocal histiocytic disorders, including Langerhans cell histiocytosis, juvenile xanthogranuloma and Rosai-Dorfman disease.
    Simko SJ; Tran HD; Jones J; Bilgi M; Beaupin LK; Coulter D; Garrington T; McCavit TL; Moore C; Rivera-Ortegón F; Shaffer L; Stork L; Turcotte L; Welsh EC; Hicks MJ; McClain KL; Allen CE
    Pediatr Blood Cancer; 2014 Mar; 61(3):479-87. PubMed ID: 24106153
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clofarabine monotherapy in aggressive, relapsed and refractory Langerhans cell histiocytosis.
    Parekh D; Lin H; Batajoo A; Peckham-Gregory E; Karri V; Stanton W; Scull B; Fleishmann R; El-Mallawany N; Eckstein OS; Prudowsky ZD; Gulati N; Agrusa JE; Ahmed AZ; Chu R; Dietz MS; Goldman SC; Hogarty MD; Imran H; Intzes S; Kim JM; Kopp LM; Levy CF; Neff P; Pillai PM; Sisk BA; Schiff DE; Trobaugh-Lotrario AD; Walkovich K; McClain KL; Allen CE
    Br J Haematol; 2024 May; 204(5):1888-1893. PubMed ID: 38501389
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Institutional experience with clofarabine and cytarabine in relapsed pediatric acute myeloid leukemia.
    Moreno L; Fernandez-Navarro JM; Del Mar Andres M; Bautista F; Tasso M; Verdeguer A
    J Pediatr Hematol Oncol; 2012 Jan; 34(1):e17-21. PubMed ID: 21716139
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sequential regimen of clofarabine, cytosine arabinoside and reduced-intensity conditioned transplantation for primary refractory acute myeloid leukemia.
    Mohty M; Malard F; Blaise D; Milpied N; Socié G; Huynh A; Reman O; Yakoub-Agha I; Furst S; Guillaume T; Tabrizi R; Vigouroux S; Peterlin P; El-Cheikh J; Moreau P; Labopin M; Chevallier P
    Haematologica; 2017 Jan; 102(1):184-191. PubMed ID: 27561720
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II trial of clofarabine with topotecan, vinorelbine, and thiotepa in pediatric patients with relapsed or refractory acute leukemia.
    Shukla N; Kobos R; Renaud T; Steinherz LJ; Steinherz PG
    Pediatr Blood Cancer; 2014 Mar; 61(3):431-5. PubMed ID: 24115731
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.